Europe Lung Cancer Therapeutics Market By Treatment Type (Chemotherapy (Cisplatin, Taxol, Navelbine, Camptosar And Alimta), Radiotherapy (External Beam, Internal Beam And Systemic) And Other Drugs (Abraxane, Avastin, Crizotinib, Docetaxel And Gefitinib)) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Europe Lung Cancer Therapeutics Market By Treatment Type (Chemotherapy (Cisplatin, Taxol, Navelbine, Camptosar And Alimta), Radiotherapy (External Beam, Internal Beam And Systemic) And Other Drugs (Abraxane, Avastin, Crizotinib, Docetaxel And Gefitinib)) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

ID: 895 | Pages: 145 | October 2018 | Region: Europe


Overview of the Market:
The Europe Lung Cancer Therapeutics Market was worth $1.67 billion in 2018 and estimated to be growing at a CAGR of 6.47%, to reach $2.29 billion by 2023. Europe is the secong largest region for the lung cancer therapeutics market.

Lung cancer is the foremost cause of cancer deaths in the European region, and the prevalence of lung cancer is cumulative significantly. It is the common cause of mortality and illness not only in developed countries but also in developing countries. Smoking is thought as a main cause of lung cancer, though lung cancer also follows in non-smokers.

Growth in the lung cancer therapeutics market is projected on account of growing prevalence rate, constant contact to radiation and carcinogens and increasing patient alertness. Furthermore, late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in rising cost of the treatment, and thus makes higher revenues for Europe treatments market.

The Europe Lung Cancer Therapeutics Market is segmented on the basis of treatment type nto Chemotherapy, Radiotherapy and Other Drugs. Based on drug type, Lung Cancer Chemotherapy market is segmented into cisplatin, taxol, navelbine, camptosar and Alimta. Based on type, Lung Cancer Radiotherapy market is segregated into external beam, internal beam and systemic. On the basis of drug type, Other Lung Cancer Therapeutic Drugs market is segmented into abraxane, avastin, crizotinib, docetaxel and Gefitinib. The top global brands that are commercially accessible in the market are Avastin, Alimta and taxol. Radiotherapy accounts for the largest segment in the lung cancer therapeutics market.

Geographical Analysis: 
Based on geography the market is analysed under various regions namely, Germany, Italy, Spain, France and U.K. U.K is the leading market due to high population base suffering from lung cancer while Germany is anticipated to witness a high growth in the forecast period.

Key Players in this Market: 
Companies are implementing various strategies to increase their product portfolio and rise its geographical presence. New product expansion, contracts and associations and procurements are some of the significant approaches adopted by the manufacturers in the lung cancer therapeutics market. The prominent players of this market include BoehringerIngelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmitKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 U.K                                

                6.3 Spain                                             

                6.4 Germany                                     

                6.5 Italy                                               

                6.6 France                                          

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 BoehringerIngelheim GmbH                               

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Hoffman-La Roche                                  

                8.3 Pfizer Inc.                                    

                8.4 GlaxoSmitKline                                         

                8.5 Eli Lilly and Company                                             

                8.6 AstrazenecaPlc                                         

                8.7 Sanofi-Aventis                                          

                8.8 Agennix AG                                

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Europe Lung Cancer Therapeutics Market By Region, From 2018-2023 (USD Billion)
  2. Europe Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  3. Europe Chemotherapy Market By Region, From 2018-2023 (USD Billion)
  4. Europe Radiotherapy Market By Region, From 2018-2023 (USD Billion)
  5. Europe Other Lung Cancer Therapeutic Drugs Market By Region, From 2018-2023 (USD Billion)
  6. U.K Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  7. Spain Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  8. Germany Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  9. Italy Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  10. France Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  11. Europe Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  12. Europe Cisplatin Market By Region, From 2018-2023 (USD Billion)
  13. Europe Taxol Market By Region, From 2018-2023 (USD Billion)
  14. Europe Navelbine Market By Region, From 2018-2023 (USD Billion)
  15. Europe Camptosar Market By Region, From 2018-2023 (USD Billion)
  16. Europe Alimta Market By Region, From 2018-2023 (USD Billion)
  17. U.K Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  18. Spain Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  19. Germany Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  20. Italy Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  21. France Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  22. Europe Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  23. Europe External Beam Market By Region, From 2018-2023 (USD Billion)
  24. Europe Internal Beam Market By Region, From 2018-2023 (USD Billion)
  25. Europe Systemic Market By Region, From 2018-2023 (USD Billion)
  26. U.K Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  27. Spain Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  28. Germany Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  29. Italy Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  30. France Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  31. Europe Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
  32. Europe Abraxane Market By Region, From 2018-2023 (USD Billion)
  33. Europe Avastin Market By Region, From 2018-2023 (USD Billion)
  34. Europe Crizotinib Market By Region, From 2018-2023 (USD Billion)
  35. Europe Docetaxel Market By Region, From 2018-2023 (USD Billion)
  36. Europe Gefitinib Market By Region, From 2018-2023 (USD Billion)
  37. U.K Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
  38. Spain Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
  39. Germany Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
  40. Italy Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
  41. France Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2019 Market Data Forecast
All Rights Reserved.